Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.

Abstract

Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.

• Authors: Thomas J Montine
• Journal: Nature reviews. Neurology (Nat Rev Neurol) Vol. 7 Issue 6 Pg. 308-9 (May 10 2011) ISSN: 1759-4766 [Electronic] England
• PMID: 21556033 (Publication Type: Journal Article)

Chemical References

• Amyloid beta-Peptides
• Biomarkers
• alpha-Synuclein
• tau Proteins

Topics

• Alzheimer Disease (diagnosis, metabolism)
• Amyloid beta-Peptides (cerebrospinal fluid, metabolism)
• Biomarkers (blood)
• Humans
• Neurodegenerative Diseases (cerebrospinal fluid, diagnosis, metabolism)
• Parkinson Disease (diagnosis, metabolism)
• alpha-Synuclein (blood)
• tau Proteins (cerebrospinal fluid, metabolism)